Sign up Australia
Proactive Investors - Run By Investors For Investors

Soleno Therapeutics shares surge on positive patent news

The firm has received a new patent (9,757,384) from the relevant US office, it said in a statement
Soleno Therapeutics shares surge on positive patent news
The firm is developing a Diazoxide Choline Controlled Release Tablet (DCCR), it said

Soleno Therapeutics Inc (NASDAQ:SLNOW) shares added almost 50% in New York as the biopharma group issued positive patent news.

The firm has received a new patent (9,757,384) from the relevant US office, related to the use of certain pharmaceutical formulations to reduce one or more aggressive behaviours in a patient with genetics disorders Prader-Willi syndrome (PWS) or Smith-Magenis syndrome (SMS).

The firm is developing a Diazoxide Choline Controlled Release Tablet (DCCR).

“This patent will further strengthen the intellectual property portfolio for DCCR, our lead product candidate, for the treatment of PWS,” said Anish Bhatnagar, Soleno Therapeutics' chief executive in a statement today.

"Importantly, this most recent patent will provide protection of associated claims into 2035. We expect to leverage additional intellectual property opportunities for DCCR over the coming months.”

Soleno expects to begin a Phase III clinical trial of DCCR in Prader-Willi syndrome (PWS) by the end of 2017.

It is now finalising the design of a randomized, double-blind placebo-controlled study to treat around 100 patients.

This study is expected to take around nine to 12 months to complete. DCCR has orphan drug status for the treatment of PWS in the USA.



Giles_55af4ddca6481.jpg


Register here to be notified of future SLNOW Company articles
View full SLNOW profile View Profile

Related Articles

Novogen: Access latest PPT from Proactive's CEO Sessions
April 13 2017
Dr James Garner talked clinical-stage programs with investors.
blood cells
October 04 2017
The two parts of the business - the commercial arm and research function - appear to be firing on all cylinders
Paradigm Biopharmaceuticals: Access latest PPT from Proactive's CEO Sessions
May 19 2017
Paul Rennie talked timeline to clinical trial results with investors.

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2017

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use